Sunlenca 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification0F
Decision 
Information 
1 issued on 
Issued1F
2 / 
affected2F
3  
amended 
on 
IB/0008/G 
This was an application for a group of variations. 
23/06/2023 
SmPC and PL 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0007 
B.I.b.2.a - Change in test procedure for AS or 
12/06/2023 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0006 
C.I.z - Changes (Safety/Efficacy) of Human and 
09/06/2023 
n/a 
Veterinary Medicinal Products - Other variation 
IAIN/0004/G 
This was an application for a group of variations. 
23/02/2023 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
IA/0003 
B.II.b.2.a - Change to importer, batch release 
21/11/2022 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
control/testing takes place 
IA/0002 
B.II.d.2.a - Change in test procedure for the finished 
19/09/2022 
n/a 
product - Minor changes to an approved test 
procedure 
IA/0001/G 
This was an application for a group of variations. 
19/09/2022 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
